Dr. Priyanka Sharma, MD
Claim this profileUniversity of Kansas Cancer Center
Studies Breast Cancer
Studies Cancer
8 reported clinical trials
22 drugs studied
Area of expertise
1Breast Cancer
Stage IV
HER2 negative
ER positive
2Cancer
HER2 negative
Stage IV
ER positive
Affiliated Hospitals
Clinical Trials Priyanka Sharma, MD is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
More about Priyanka Sharma, MD
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Priyanka Sharma, MD has experience with
- Pembrolizumab
- Docetaxel
- Carboplatin
- Biospecimen Collection
- Cyclophosphamide
- Doxorubicin
Breakdown of trials Priyanka Sharma, MD has run
Breast Cancer
Cancer
Brain Metastasis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Priyanka Sharma, MD specialize in?
Priyanka Sharma, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Priyanka Sharma, MD currently recruiting for clinical trials?
Yes, Priyanka Sharma, MD is currently recruiting for 4 clinical trials in Kansas City Kansas. If you're interested in participating, you should apply.
Are there any treatments that Priyanka Sharma, MD has studied deeply?
Yes, Priyanka Sharma, MD has studied treatments such as Pembrolizumab, Docetaxel, Carboplatin.
What is the best way to schedule an appointment with Priyanka Sharma, MD?
Apply for one of the trials that Priyanka Sharma, MD is conducting.
What is the office address of Priyanka Sharma, MD?
The office of Priyanka Sharma, MD is located at: University of Kansas Cancer Center, Kansas City, Kansas 66205 United States. This is the address for their practice at the University of Kansas Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.